NASDAQ$VTYX
Ventyx Biosciences Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Reported second quarter 2024 financial results and highlighted recent corporate progress.
Ventyx Biosciences reported a net loss of $32.0 million for the second quarter of 2024, with cash, cash equivalents, and marketable securities totaling $279.7 million as of June 30, 2024. The company is planning to advance its portfolio of NLRP3 inhibitors into three Phase 2 clinical trials and expects clinical updates from all three trials in 2025.
- Phase 2 obesity and cardiometabolic trial and Phase 2a trial in Parkinson’s disease for VTX3232 are expected to initiate in H2 2024.
- Phase 2 trial of VTX2735 in recurrent pericarditis is expected to initiate in H2 2024.
- Mark Forman, MD, PhD will join Ventyx as Chief Medical Officer effective August 12, 2024.
- Cash, cash equivalents and marketable securities of $279.7 million as of June 30, 2024 are expected to fund planned operations into at least the second half of 2026.
Headline financials
Revenue & EPS history
Ventyx Biosciences · Revenue · Quarterly
$0
Forward guidance
Ventyx anticipates continued progression of its development pipeline and has sufficient funds to support operations into the second half of 2026. The company plans to present long-term extension data from the Phase 2 study of VTX002 in UC and is seeking a partner for a Phase 3 trial.
Tailwinds
- Phase 2a trials of VTX3232 in Parkinson’s disease and obesity and cardiometabolic diseases are expected to initiate in H2 2024.
- Phase 2 trial of VTX2735 in recurrent pericarditis is expected to initiate in H2 2024.
- Clinical updates for all three studies are expected in 2025.
- The LTE data from the Phase 2 study of VTX002 in UC will be presented.
- The company anticipates funding operations with current resources into at least the second half of 2026.
Headwinds
- Potential delays in the commencement, enrollment, and completion of clinical trials.
- Dependence on third parties in connection with product manufacturing, research, and preclinical and clinical testing.
- Disruptions in the supply chain.
- Unexpected adverse side effects or inadequate efficacy of Ventyx’s product candidates.
- The use of capital resources by Ventyx sooner than expected.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 8 quarterly earnings reports · overlaid with Q2 2024
+4.2%
Avg return
Earnings day
+7.1%
Avg return
5 days after
+13.8%
Avg return
30 days after
56%
10 / 18 earnings
Positive
+34.4%
Q2 2022
Best reaction
-11.9%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | -5.7% | +2.5% | -6.0% | |
| Q2 2025 | +18.4% | +20.5% | +6.8% | |
| Q1 2025 | +7.0% | +1.8% | +113.2% | |
| Q4 2024 | +9.0% | +4.2% | -16.1% | |
| Q3 2024 | -5.6% | -10.0% | +34.2% | |
| Q2 2024 | +5.6% | -0.5% | +10.9% | |
| Q1 2024 | -7.9% | -6.3% | -26.4% | |
| Q4 2023 | +32.6% | +45.0% | -6.5% | |
| Q3 2023 | -11.9% | — | — | |
| Q2 2023 | +1.9% | — | — | |
| Q1 2023 | -11.6% | — | — | |
| Q4 2022 | -8.3% | — | — | |
| Q3 2022 | -9.1% | — | — | |
| Q2 2022 | +34.4% | — | — | |
| Q1 2022 | +10.6% | — | — | |
| Q2 2021 | +9.3% | — | — | |
| Q4 2021 | +9.3% | — | — | |
| Q3 2021 | -1.7% | — | — | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro